在患有慢性炎症性脱髓化多神经病症 (CIDP) 的患者中,阿扎西奥普林和甲索特酸的有效性
Shamza Mehreen1, Sadaf Iftikhar1, Ali Muhammad1
1Department of Neurology, King Edward Medical University/ Mayo Hospital, Lahore, Pakistan.
Pakistan journal of pharmaceutical sciences
|August 22, 2023
概括
阿扎西奥普林在治疗慢性炎症性脱髓化多神经病 (CIDP) 方面表现出比美托雷克萨特更高的疗效. 这一发现表明,阿扎西奥普林作为首选的第一线免疫抑制剂用于CIDP,特别是在资源有限的环境中.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性炎症性脱髓性多神经病 (CIDP) 是一种衰弱的神经疾病,需要有效的免疫抑制疗法.
- 目前对CIDP的治疗选择具有不同的疗效和副作用,需要进行比较研究.
研究的目的:
- 为了比较阿扎西奥普林 (AZA) 与甲索 (MTX) 在CIDP患者中作为免疫抑制剂的疗效.
- 评估AZA和MTX在改善CIDP患者神经功能方面的长期有效性.
主要方法:
- 根据科斯基标准,对成年患者诊断出CIDP的比较研究.
- 患者接受了前列尼索隆与阿扎西奥普林 (第一组) 或前列尼索隆与甲托雷克萨特 (第二组) 的治疗.
- 神经功能在基线,3个月和12个月使用整体神经病症限制量表 (ONLS) 进行评估.
主要成果:
- 在最初的三个月内,阿扎西奥普林和甲索特雷克萨特组之间的初始ONLS分数与阿扎西奥普林和甲索特雷克萨特组相似.
- 与甲索特雷克萨特组相比,阿扎西奥普林组在第四个月的ONLS分数中显示出统计学上显著的改善.
- 在12个月后,阿扎西奥普林组 (3.69) 的平均ONLS得分明显低于甲索特雷克萨特组 (5.30) (p=0.001).
结论:
- 在12个月的时间内,阿扎西奥普林在改善CIDP患者的神经功能方面比美托雷克萨特更有效.
- 亚扎西奥普林应该被认为是首选的第一线免疫抑制剂用于CIDP治疗,特别是在低收入国家.
- 进一步的研究可能会探索阿扎西奥普林在CIDP管理中的长期安全性和成本效益.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
Drugs for Treatment of Ulcerative Colitis in IBD
173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
150
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
150
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K


